BYSI News and Press, BeyondSpring Inc. From 10/21/21

—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S. —In the Phase 1 study, plinabulin combination was able to induce tumor responses in patients who had progressed on platinum and checkpoint inhibitors,...

Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC 70 of 35 nM The preclinical data is consistent with clinical ...

Posting the third consecutive weekly loss, the healthcare stocks in the S&P 500 fell ~0.4% over the week. While healthcare became the fourth worst performing sector, the broader index edged ~0.5% higher during the week. Among healthcare stocks with more than $300M market cap and...

Evercore ISI has set up its list of key catalysts for the rest of 2021 in the biotechnology sector - including early-stage data readouts as well as some important legal and regulatory updates ahead for particular companies. Along the way it tees up its rule of thumb on biotech catalysts: "Alw...

BeyondSpring Inc. (NSC:BYSI), a company whose shares are moving quickly, is trading 32.6% lower to $15.50. BeyondSpring Inc. share prices have moved between a 52-week high of $33.00 and a 52-week low of $8.90 and are now trading 74% above that low price at $15.50 per share. Receive IBN...

Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...

The major averages were down more than 2% in Monday's midday trading, accelerating a decline that has marked most of September so far. Still, even in the general sell-off, some individual stock stories drew added attention. Auto suppliers outpaced the overall decline in the broader averages. ...

Shares of BeyondSpring Inc ( NASDAQ: BYSI ) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung cancer. This morning, however, the stock tanked over 25% as STAT (American heal...

Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...

Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for the combination (DP) vs. docetaxel (D). Study met key secondary endpoints showing statistically significant improvement for DP vs. D in ORR, PFS, and 24- and 36-month OS r...